Transcriptional Activation of *Mina* by Sp1/3 Factors

Shangli Lian, Hari Hara S. K. Potula, Meenu R. Pillai, Melanie Van Stry, Madoka Koyanagi, Linda Chung, Makiko Watanabe, Mark Bix*

Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

**Abstract**

*Mina* is an epigenetic gene regulatory protein known to function in multiple physiological and pathological contexts, including pulmonary inflammation, cell proliferation, cancer and immunity. We showed previously that the level of *Mina* gene expression is subject to natural genetic variation linked to 21 SNPs occurring in the *Mina* 5' region [1]. In order to explore the mechanisms regulating *Mina* gene expression, we set out to molecularly characterize the *Mina* promoter in the region encompassing these SNPs. We used three kinds of assays – reporter, gel shift and chromatin immunoprecipitation – to analyze a 2 kb genomic fragment spanning the upstream and intron 1 regions flanking exon 1. Here we discovered a pair of *Mina* promoters (P1 and P2) and a P1-specific enhancer element (E1). Pharmacologic inhibition and siRNA knockdown experiments suggested that Sp1/3 transcription factors trigger *Mina* expression through additive activity targeted to a cluster of four Sp1/3 binding sites forming the P1 promoter. These results set the stage for comprehensive analysis of *Mina* gene regulation from the context of tissue specificity, the impact of inherited genetic variation and the nature of upstream signaling pathways.

**Introduction**

The JmJC family protein *Mina* has been implicated in immune function, cell proliferation and cancer. Tsuneoka et al first discovered *Mina* as a 53 Kd Myc-induced nuclear antigen with the capacity to regulate cell proliferation [2,3]. High level MINA expression in tumor biopsies has been linked to poor prognosis in a variety of human cancers. These include colon cancer, esophageal squamous cell carcinoma, renal cell carcinoma, lymphoma, neuroblastoma, gastric carcinoma, hepatocellular carcinoma and lung cancer [2,4–13]. More recently, *Mina* was found to control T helper (Th) 2, Th17 and T regulatory cell differentiation [1,14].

Given clear evidence of *Mina*'s involvement in immunity, cell proliferation and cancer, it is important to understand how *Mina* expression is regulated. We know from analysis of protein turnover and pre-mRNA transcription rate that *Mina* protein abundance is controlled largely at the translational level [1]. However, the mechanisms governing *Mina* transcription remain poorly understood. To begin addressing this gap, we report here the molecular characterization of the *Mina* promoter region and its trans-acting factors in murine T cells. Using a dual luciferase reporter assay to interrogate nested deletions of a region spanning the *Mina* transcriptional start site (TSS), we defined a 144 bp minimal *Mina* promoter encompassing four potential Sp1/3 binding sites. Gel shift assays validated all sites as functional for Sp1 and Sp3 binding.

Furthermore, mutagenesis analysis demonstrated that full reporter activity required WT sequence at all 4 Sp1/3 binding sites. Pharmacological inhibition and siRNA knockdown of Sp1/3 binding activity and level, respectively, substantially diminished *Mina* mRNA expression. Finally, chromatin immunoprecipitation (ChIP) assays in primary T helper cells revealed the *Mina* promoter region to be enriched in bound Sp1 and Sp3 as well as lysine-4 trimethylated histone H3 (H3K4me3), a marker of transcriptionally active chromatin. Together, these results indicate a physiolog-ical requirement of Sp1 and Sp3 for *Mina* transcription and provide a stimulus for analysis of potential distal regulatory elements and the upstream pathways responsible for the tight regulation of *Mina* expression in its diverse physiological contexts.

**Materials and Methods**

**Ethics Statement**

Mice used in this study were maintained in specific pathogen-free conditions in accordance with the guidelines of the Institutional Animal Care and Use Committee of St. Jude Children’s Research Hospital under protocol 453 approved by the St. Jude Institutional Animal Care and Use Committee.

**Mice**

BALB/c and C57BL/6 mice were purchased from Jackson Lab.

**Reagents and Antibodies**

Anti-TCR β was purified from hybridoma H57.597. Anti-CD28 was purchased from Biolegend (102102). Anti-Mina antibody was purchased from Zymed (clone M532). Anti-H3K4me3 (07–030) and anti-H3K27me3 (07–449) antibodies were purchased from Upstate (Millipore). Isotype control Rabbit IgG (AB46540-1), Mouse IgG (AB18413) and Goat IgG (AB37373) were purchased.

*E-mail: mark.bix@stjude.org*
from Abcam. Sp1 (PEP 2, sc-59), Sp3 (D-20, sc-644), RUNX3 (sc-23576X), and YY1 (sc-1703X) were purchased from Santa Cruz. Mouse recombinant IL-2 (354078 BD) was used at 20 U/ml. Mithramycin A (M6891) was purchased from Sigma-Aldrich. Poly dA:dT (Cat# tlrl-patn) was purchased from InvivoGen. ChIP-grade Protein G Magnetic Beads (Cat# 9006) were purchased from Cell Signaling.

Cloning
A 2 kb Mina proximal promoter region (−1588 to +351) was PCR amplified from Mus musculus BAC clone RP23-2304 (AC154854) using forward primer 5'-TCAATGAGAAAGGGGCCT-3' and reverse primer 5'-CAACCTAGGCTCAAAGTC-3'. The 2 kb fragment was then cloned into PGL3 basic vector (Promega) to drive firefly luciferase (FL) expression. 5' and 3' nested deletions were generated using the Erase-a-Base system (Promega). The Mina promoter fragment (−64 to +151) was amplified using forward primer 5'-ATATATGATATCAGAGCTGCACTTCTCAGCCTGA-3' and reverse primer 5'-ATATATGATATCAGAGCTGCACTTCTCAGCCTGA-3', and then cloned into the EcoRV site of PGL3 basic vector. Mutagenesis of Sp1/3 binding sites was performed on Mina promoter (−64 to +151) using QuickChange II-E Site-Directed Mutagenesis Kit (Cat# 200555, Agilent Technologies).

Cell Culture
EL4 cells were cultured in RPMI containing 10% FBS, penicillin/streptomycin (GIBCO 15140), L-Glu (GIBCO 25030) and β-mercaptoethanol (GIBCO 21985). 1×10^6 EL4 cells were treated for 24 h with 10 nM, 100 nM, 1 mM Mithramycin or 1 mM DMSO as carrier control.

Luciferase Assay
Lipofectamine LTX with Plus reagent (Invitrogen) was used to cotransfect EL4 cells (2×10^5) with PGL3 reporter constructs expressing firefly luciferase (FL) (750 ng) and pRL-TK expressing control renilla luciferase (RL) (40 ng). Following 48 h culture in 24 well plates, cells were harvested and assayed for FL and RL activity using the Dual-Luciferase Reporter Assay System (Promega).

Electrophoretic Mobility Shift Assay
EL4 cell nuclear extracts were prepared with the NER-PER extraction kit (Pierce, 78833). Protein concentrations were determined using the Bradford Assay (Thermo Scientific, 1856209) and bovine serum albumin as a standard (Sigma A9418). Probes were generated by annealing 5' biotin-labeled oligonucleotides at 95°C in annealing buffer (100 mM Tris pH 7.5, 10 mM EDTA, 2 M NaCl, 50 mM MgCl2) followed by slow cooling to 22°C (~5 hrs). Probe sequences are given in Table S1. Nuclear extracts (10 μg), Poly (dA:dT) (1 μg), and biotinylated probes (200 fmol) were incubated together at 22°C for 30 min in 20 μl binding buffer (10 mM Tris pH 7.5, 60 mM KCl, 2 mM MgCl2, 0.15 mM dithiothreitol). For competition, 100-fold molar excess of unlabeled probe (20 pmol) was added to the reaction before adding biotinylated probe. For supershift, antibody (2 μg) was included in the reaction for 15 min before biotinylated probe was added. Binding reactions were resolved on 0.5X TBE 4% polyacrylamide gels at 150 V for 2-3 hr, transferred to nitrocellulose for 30 min at 4°C, and then UV crosslinked for 45-60
second using the auto crosslink function of the UV-light crosslinking instrument (Stratagene). Probe signals were detected using the Chemiluminescent Nucleic Acid Detection Module kit (Cat #89880, Pierce).

Chromatin Immunoprecipitation (ChIP) Assay

EL4 cells were fixed in 1% formaldehyde for 15 min at RT. 10\(\times\)10^6 nuclei (isolated as described for FAIRE in [15]) were resuspended in 350 \(\mu\)l Buffer 3 [21] and sonicated using a BioRuptor (Diagenode) until the average chromatin fragment size was \(\sim 500\) bp. Sonicated samples were centrifuged at 16,000 g for 10 min at RT and supernatants diluted 1 to 8 in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM TrisHCl pH8, 1X protease inhibitor). Immunoprecipitation was performed by combining 1 ml of diluted supernatant (~4\(\times\)10^6 nuclei) with 4 \(\mu\)g of antibody or corresponding IgG control and overnight rotation at 4°C. Beads were separated by incubation on a magnet rack and washed sequentially with 1 ml of the following buffers: Par Wash 1# (1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM TrisHCl pH8, 150 mM NaCl, 1X protease inhibitor), Par Wash 2# (1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM TrisHCl pH8, 500 mM NaCl, 1X protease inhibitor), Par Wash 3# (1 mM EDTA, 10 mM TrisHCl pH8, 250 mM LiCl, 1% NP-40, 1% DOC, 1X protease inhibitor), and TE buffer. Each wash was performed by 5 min rotation at RT. Elution of DNA/protein complexes was performed by adding 8 \(\mu\)l freshly made elution buffer (0.1 M NaHCO3/1% SDS), vortexing, and 10 min rotation at RT. A second elution was combined with the first for a total volume of 200 \(\mu\)l. Crosslinks were reversed by adding 8 \(\mu\)l of 5 M NaCl to the combined eluates followed by overnight incubation at 65°C. DNA was purified by adding 20 \(\mu\)l of protein digestion buffer (0.4 M Tris-HCl, pH 6.8, 0.1 M EDTA, 0.8 mg/ml Proteinase K), mixing, incubation for 1 h at 50°C and phenol/chloroform extraction. The purified DNA pellet was dried and resuspended in 20 \(\mu\)l of water. Quantitative real time PCR was performed to measure the relative enrichment of Mina promoter and Mina intron 2 DNA sequences. Primer sequences are given in Table S1.

For ChIP performed with CD4 T cells, lymphocytes were isolated from spleen and lymph nodes of C57BL/6 or BALB/c mice, sorted for CD4^+ /CD62L^+ /CD44^2 /CD25^2 T cells, and cultured for 6–8 h in 6-well plates coated with 0.1 \(\mu\)g/ml anti-TCR\(\beta\) and 10 \(\mu\)g/ml anti-CD28 (Biolegend). Cells were harvested

![Figure 2. Electrophoretic mobility shift (EMSA) analysis of four consensus Sp1/3 binding sequences comprising the Mina P1 promoter.](https://example.com/figure2.png)

(A) Shown is the sequence of the Mina P1 promoter mapped to region (~64/+19) showing the TSS (bent arrow), the four consensus Sp1/3 binding sequences (boxed and shaded), and probes p1–p4 each containing a single Sp1/3 site (underlined and labeled). (B) Representative EMSA assay showing nucleoprotein complexes 1 and 2 (arrows) formed by combining nuclear extracts from EL4 cells with 5’ biotin labeled probes p1–p4 in the absence or presence of a 100-fold molar excess of unlabeled probes containing autologous (p1–p4) and heterologous (A and B corresponding to Sp1A and Sp1B, respectively, from the OX40 promoter [16]) Sp1/3 consensus sequences. Data are representative of 2 experiments. doi:10.1371/journal.pone.0080638.g002

Mina Activation by Sp1/Sp3
and fixed in 1% formaldehyde at RT for 10 min and then processed as described above.

Quantitative Real-Time (RT) PCR

Total RNA was extracted with TRIzol reagent (Invitrogen) and cDNA synthesized using SuperScript III Reverse Transcriptase (Invitrogen). Quantitative real-time PCR was performed using iQ SYBR Green Supermix on Real-Time Detection System (Applied Biosystems) or MX4000 real-time PCR system (Stratagene). Primers for detecting Mina, Gapdh and Hprt were described before [1]. Primers for Sp1 and Sp3 are as follows: Sp1 Forward 5’-ACCATGAGCGACCAAGATCA-3’ and Sp1 Reverse 5’-CATTGCCGCTACCCCCATTA-3’; Sp3 Forward 5’-ACCTGAAGAATGGCAGCTC-3’ and Sp3 Reverse 5’-GGTACCTCTCCCACCACCTT-3’. mRNA level was normalized to house keeping genes Hprt and Gapdh.

siRNA Interference

EL4 cells were transfected in 96-well plates with Accell siRNA transfection reagent (Thermo scientific Dharmacon; non-specific siRNA, D-001910-10-05; Sp1 siRNA, E-040633-00-0005; Sp3 siRNA, E-040397-00-0005) and cultured for 72 hours prior to RNA harvest and analysis by quantitative RT-PCR.

Results

Two Promoters and an Enhancer in the Mina TSS-proximal Region

To map the Mina promoter, a ~2 kb-fragment spanning the transcriptional start site (TSS) from position −1588 to +354 was cloned into PGL3 basic vector and tested for reporter activity by dual luciferase assay in the thymoma cell line EL4 (Fig. 1, gray filled arrow). Fragment (−1588/+354) contained strong reporter activity, respectively, 6- and 60-fold higher than that driven by the SV40 promoter and by vector alone (Fig. 1). To characterize this activity, we interrogated a panel of 5 nested deletions of fragment (−1588/+354) by reporter assay. Whereas deletions extending as far as position −64 had no impact, removal of an additional 83 base pairs to position +19 caused a dramatic drop but not complete abolition of activity (Fig. 1). These results suggested: (1) that region (−64/+19) contains an element that mediates strong reporter activity suggestive of an enhancer; and (2) that fragment (+19/+354) contains a Mina promoter (termed P2; Fig. 1, rightmost dark gray rectangle) comparable in activity to the SV40 promoter. To further localize P2 within fragment (+19/+354), two additional 5’ deletions were generated and tested. One, extending as far as position +150, maintained P2 activity, whereas a second deletion extending to +280 completely abolished it.
These results narrow the location of P2 to region (+150/+280) (Fig. 1, rightmost dark gray rectangle).

In order to reconcile the enhancer-like magnitude of the activity mapping to region (+64/+19) and its promoter-like position spanning the Mina TSS, we hypothesized that it might encompass a second Mina promoter that is selectively targeted by a distal enhancer contained within fragment (+64/+354). To test this hypothesis, we generated the TSS-spanning fragment (+264/+80) and found it to exhibit low-level reporter activity similar to the SV40 promoter and to P2 (Fig. 1). Thus, the high-level reporter activity located within fragment (+64/+354) and mapping to region (+64/+19) is likely due to a second promoter (termed P1; Fig. 1, leftmost dark gray rectangle) targeted by a P1-specific distal enhancer (termed E1) mapping to region (+80/+354). The low-rather than high-level activity of fragment (+19/+354) – lacking P1 and containing both P2 and E1 – provides further evidence for the P1-specificity of E1.

In summary, two promoters were identified in a ~2 kb Mina TSS-spanning genomic fragment: P1 in region (+64/+19) and P2 in region (+150/+280). Further, we inferred the existence of a P1-specific enhancer E1 located in region (+80/+354).

### Four Sp1/3 Binding Sites Spanning the Mina P1 Promoter

Given its TSS-spanning location and its specific regulation by E1, we decided to focus on characterizing P1. Using Transfac software (Biobase), we identified a cluster of four predicted Sp1/3 binding sites spanning region (+264/+19) (Fig. 2A). To begin exploring whether any of these sites were functional, we performed gel shift assays with DNA probes (p1–p4) spanning each site and nuclear extract from the Mina-expressing EL4 murine thymoma cell line.
Binding of Sp1/3 to the Mina P1 Promoter in EL4 Cells

Next, we investigated whether Sp1 and/or Sp3 occurred within nucleoprotein complexes 1 and 2. Using gel shift assays, we found that antibodies against YY1, Runx3 and Mina failed to perturb either complex (Fig. 3A). By contrast, an Sp1-specific antibody caused a supershift of the upper band of the complex 1 doublet, while an Sp3-specific antibody abolished the lower band of the complex 1 doublet and the upper band of the complex 2 doublet. Combining antibodies against Sp1 and Sp3 led to a summation of their individual effects on complexes 1 and 2 (Fig. 3A). Together, these data indicate that probes p1–p4 each form 3 distinct nucleoprotein complexes, one containing Sp1 and two containing Sp3.

Next, to examine whether Sp1 and/or Sp3 bind the Mina promoter in EL4 cells, we performed chromatin immunoprecipitation experiments using control IgG and antibodies against Sp1 and Sp3. As shown in Figure 3B and C, a Mina intron 2 sequence ∼6 kb downstream of the Mina P1 promoter was similarly enriched in chromatin immunoprecipitated with Sp1- and Sp3-specific antibodies as with control IgG. By contrast, a Mina P1-proximal sequence was enriched to a significantly greater extent in chromatin immunoprecipitated with Sp1 or Sp3 antibodies as compared to control IgG. These data indicate that both Sp1 and Sp3 bind the Mina P1 promoter in EL4 cells.

Regulation of Mina Expression by Sp1/3

To extend our cell-free and cellular evidence that Sp1 and Sp3 bind to the Sp1/3 sites in the Mina P1 promoter, we asked next whether Sp1/3 factors regulate Mina P1 promoter activity. First, to map the key nucleotides required for Sp1/3 binding to each of the four Sp1/3 sites (Sp1.1–1.4), we performed gel shift assays on sets of six probe-spanning mutants. For Sp1.1, we found that probe p1 mutants M5, M4 and M5 exhibited impaired formation of complexes 1 and 2 (Fig. 4A). Similarly, we identified mutants of p1, p2 and p3 that disrupted Sp1/3-binding to Sp1.2, Sp1.3 and Sp1.4, respectively (Fig. 4B–D). Together, these data provide further evidence that each Sp1/3 site is functional for Sp1/3 binding and set the stage for functional analysis.

To explore whether Sp1/3 regulates Mina P1 promoter activity via any of its four Sp1/3 sites, we performed site-directed mutagenesis to introduce the relevant mutations (as determined by gel shift assay above) in each or combinations of the four Sp1/3 sites (Fig. 4E). Individual Sp1/3 site mutations did not significantly decrease reporter activity. By contrast, combinations of two or three Sp1/3 site mutations led to impaired reporter activity, while simultaneous mutation of all four Sp1/3 sites completely abolished P1 promoter activity (Fig. 4E). Together, these data show that binding of Sp1/3 to each of the four Sp1/3 sites contributes additively to the activation of the Mina P1 promoter.

To explore whether Sp1/3 contributes to endogenous Mina transcription in EL4 cells, we treated cells for 24 h with Mithramycin A or vehicle alone. Mithramycin A is known to specifically inhibit Sp1 binding to its consensus GC-rich binding sites and impair its ability to promote transcription [17]. In cells treated with 1 μM Mithramycin Mina transcript level decreased more than 50% in comparison to control-treated cells (Fig. 4F). Mithramycin did not inhibit Hprt expression (data not shown). To further extend these results, we performed siRNA knockdown of Sp1/3 in EL4 cells. Treatment of cells with non-specific siRNA had no detectable effects on Sp1, Sp3 or Mina expression (Fig. 5). An Sp1-targeted siRNA abolished Sp1 but not Sp3 expression whereas an Sp3-targeted siRNA was found to impair expression of both Sp3 and Sp1. Strikingly, both the Sp1- and Sp3-targeted siRNAs abolished Mina expression. Together, these data suggest that in T cells Mina gene transcription from its P1 promoter requires Sp1.

Binding of Sp1/3 to the H3K4me3-enriched Mina P1 Promoter in Primary T Cells

We chose to explore Sp1/3 binding to the endogenous Mina promoter in primary naïve (CD4+CD25−CD44+CD62Lhigh) CD4 T lymphocytes as they are known to express Mina at high level [1]. We assessed the enrichment of Mina P1 promoter-proximal and distal intron 2 sequences in chromatin immunoprecipitated with control IgG and antibodies against Sp1 and Sp3. As was the case with EL4 cells (Fig. 3B and C) we found that in
primary naïve CD4 T cells both Sp1 and Sp3 bound to the Mina P1 promoter but not to distal intron2 (Fig. 6A and B).

Histone modifications are implicated in regulating gene expression by modulating chromatin structure, DNA accessibility and recruitment of transcription regulatory machinery [18,19]. Tri-methylation of histone 3 at lysine 4 (H3K4me3) marks the promoters of actively transcribed genes, whereas tri-methylation of histone 3 at lysine 27 (H3K27me3) is associated with gene repression and silenced chromatin [20]. To determine whether the epigenetic landscape of the Mina locus correlated with its transcriptional status and Sp1/3 binding to the P1 promoter, chromatin fragments from naive CD4 T cells of C57BL/6 mice were immunoprecipitated with antibody to either H3K27me3 or H3K4me3, and then subjected to high-throughput sequencing (ChIPseq). The ChIPseq signals from both anti-H3K27me3 (upper panel) and anti-H3K4me3 (lower panel) are shown with correlations to the Mina locus. The depth of the peaks in the histograms corresponds to the number of reads mapped to the location. A schematic of the Mina locus is shown above the histograms. Each box represents an exon. The region that enriched for H3K4me3 but was devoid of H3K27me3 modifications is enlarged and shown above the Mina locus schematic. (B–C) ChIP assay confirmed the binding of Sp1 and Sp3 to the Mina promoter in EL4 cells. Chromatin fragments from CD4+CD62LHiCD44−CD25−T cells of BALB/c mice were immunoprecipitated with antibodies against Sp1 (B, open bars), Sp3 (C, open bars), or their corresponding IgG controls (B–C, filled bars). Promoter: Mina promoter region; Intron 2: an Intron 2 region located −6 kb downstream of the Mina promoter.

doi:10.1371/journal.pone.0080638.g006

Discussion

In the current study we sought to characterize the Mina promoter region by exploring the transcriptional regulatory elements occurring within a 2 kb interval spanning the Mina TSS. We identified two promoters, termed P1 and P2, respectively mapping to region (−64/+19) spanning the TSS and to region (+150/+280) spanning exon 1 and intron 1. Three main murine Mina mRNA isoforms are documented in AceView [22]. The first of these initiates 14 bp downstream of P2. The 2nd and 3rd initiate, respectively, 11 bp downstream of and within P1. The correlation between the locations of P1 and P2 mapped in our study and the TSSs documented in AceView support our finding that Mina contains 2 promoters. Interestingly, we detected an enhancer-like element (termed E1) occurring within region (+80/+150) that could strongly promote reporter activity from P1 but not P2. P1 was found to contain four functional Sp1/3 sites that acted
synergistically to promote reporter activity and bound both Sp1 and Sp3 in EL4 cells and primary CD4 T cells. Pharmacological inhibition of Sp1/3 binding in EL4 cells diminished the level of Mina transcription. Finally, the epigenetic landscape of H3K4me3 and H3K27me3 modifications (marking transcriptionally active and silent chromatin regions, respectively) across the Mina locus in primary CD4 T cells revealed a striking peak of H3K4me3 at the promoter region and an unexpected bivalent domain (simultaneously enriched in both H3 modifications) spanning most of intron 1. Taken together, our study provides strong support for a central role of Sp1/3 factors in regulating Mina transcription through binding to a cluster of 4 Sp1/3 sites in the Mina P1 promoter.

The precise location of the E1 enhancer (up- or down-stream of P2), the mechanism underlying its specificity for P1 versus P2, the nature of the transcription factor(s) that bind to and mediate P2 promoter activity and the relative roles of Mina P1 and P2 are currently under investigation. Interestingly, we detected a potential myeloid zinc finger 1 (Mzf1) binding site in P2 (data not shown). Mzf1 is preferentially expressed in myeloid cells and controls hematopoiesis [23]. It is tempting to postulate that through P2 Mzf1 may control Mina transcription in dendritic cells, another cell type where Mina is highly expressed and may function.

Sp1 and Sp3 are well-known transcription factors that modulate transcription of TATA-less genes by interacting directly with and mediating recruitment to basal transcription machinery [24–27]. They are deregulated in various types of human cancer. Sp1 mRNA and DNA-binding activities are shown to increase in epithelial tumors, suggesting that increased Sp1 activity contributes to skin tumor progression [28]. Further, Sp1/3 is constitutively overexpressed in pancreatic and gastric cancers and many signal transduction pathways terminating on Sp1-regulated genes are linked to cancer progression [29–31]. Given that Mina is aberrantly expressed in many cancers, it is tempting to speculate that its transcriptional regulation by Sp1/3 may contribute to its roles in cell proliferation and oncogenesis.

Sp1/3 factors also play a prominent role in the immune system, being known to regulate transcription of cytokines and regulators of T cell homeostasis, activation and differentiation, including GM-CSF [32], IL-10 [33,34] and OX40 [16]. Interestingly, Sp1/3 contributes to the differential expression of Fas ligand (a critical component of peripheral T cell homeostasis and cytotoxic effector mechanisms), Eta-1 (a cytokine that regulates IL-10 expression and Th1 polarization), and FUT7 (the rate-limiting enzyme for synthesis of a lymphocyte homing ligand) in Th1 and Th2 cells either through differential binding to a promoter polymorphism [35] or through differential promoter recruitment of transcription factors [36,37]. Further, Sp1/3 regulates the promoter activity of the IL4 receptor alpha chain [38], through which IL4 exerts its critical biological effects, including promotion of Th2 differentiation. We postulate that orchestration of effector T cell differentiation by master transcriptional regulators involves Sp1/3-dependent transcription of Mina.

The Mina P1 promoter appears to be able to buffer genetic variation insofar as mutations abolishing Sp1/3 binding to as many as two binding sites still permitted a level of activity not significantly different from the WT promoter with 4 functional Sp1/3 binding sites. This might also explain why 1 μM Mitramycin A was required to impair endogenous Mina transcription, whereas 10-fold less was sufficient to inhibit transcription of an Sp1/3 target gene (TINF2) that contained only two Sp1/3 sites [39].

This work sets the stage for a comprehensive analysis of Mina regulatory elements (enhancers and silencers) and for the discovery of regulatory SNPs that modulate Mina expression level across strains with high and low Th2-bias.

Supporting Information

Table S1 Electromobility shift and ChIP assay primers and probes. (DOCX)

Acknowledgments

We thank Melanie Van Stry for getting the project off the ground; the Cellular Immunology Core, Immunology Flow Cytometry Core and Animal Resources Centre of St. Jude Children’s Research Hospital for expert technical support; Daniel McGoldrick for help with ChIPseq.

Author Contributions

Conceived and designed the experiments: SL MB. Performed the experiments: SL HP MK LC MW. Analyzed the data: SL MW MB. Contributed reagents/materials/analysis tools: SL MK LC MW. Wrote the paper: SL MB.

References

1. Okamoto M, Van Stry M, Chung I, Koyanagi M, Sun X, et al. (2009) Mina, an I4 repressor, controls T helper type 2 bias. Nature Immunology 10: 872–879.
2. Tsuneoka M, Koda Y, Soejima M, Teye K, Kimura H (2002) A novel myc target gene, mina53, that is involved in cell proliferation. J Biol Chem 277: 35450–35459.
3. Zhang Y, Lu Y, Yuan BZ, Castranova V, Shi X, et al. (2005) The human mineral dust-induced gene, mdg, is a cell growth regulating gene associated with lung cancer. Oncogene 24: 4873–4882.
4. Teye K, Tsuneoka M, Arima N, Koda Y, Nakamura Y, et al. (2004) Increased expression of a Myc target gene, Mina53, in human colon cancer. Am J Pathol 164: 205–216.
5. Kuramoto K, Kusukawa J (2006) Immunohistochemical expression of Mina53 and KIF6 proteins in human primary gingival squamous cell carcinoma. The Kurume medical journal 53: 71–78.
6. Tsuneoka M, Fujita H, Arima N, Teye K, Okamura T, et al. (2004) Mina53 as a potential prognostic factor for esophageal squamous cell carcinoma. Clin Cancer Res 10: 7347–7356.
7. Ishizaki H, Yano H, Ogasawara S, Akiba J, Nishida N, et al. (2007) Expression of the myc target gene Mina53 in advanced renal cell carcinoma. Pathol Int 57: 672–680.
8. Teye K, Arima N, Nakamura Y, Sakamoto K, Sueoka E, et al. (2007) Expression of Myc target gene mina53 in subtypes of human lymphoma. Oncol Rep 18: 841–848.
9. Fukahori S, Yano H, Tsuneoka M, Tanaka Y, Yagi M, et al. (2007) Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma. J Pediatr Surg 42: 1031–1040.
10. Zhang Q, Hu GM, Yuan YS, He CH, Zhao Q, et al. (2008) Expression of Mina53 and its significance in gastric carcinoma. Int J Biol Markers 23: 83–88.
11. Ogasawara S, Komuta M, Nakashima O, Akiba J, Tsuneoka M, et al. (2010) Accelerated expression of a Myc target gene Mina53 in aggressive hepatocellular carcinoma. Hepatol Res 40: 330–336.
12. Komiyama K, Sasaoka-Aragane N, Sato A, Hisatomi T, Sakuragi T, et al. (2010) Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer. Lung Cancer 69: 232–238.
13. Komiyama K, Sasaoka-Aragane N, Sato A, Hisatomi T, Sakuragi T, et al. (2010) Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/ST3 cells. J Cancer Res Clin Oncol 136: 463–473.
14. Yoshifuku S, Shalek AK, Gauthier RE, Jin H, Lee Y, et al. (2013) Dynamic regulatory network controlling TH17 cell differentiation. Nature 496: 461–468.
15. Giese PA, Lieb JD (2009) Isolation of active regulatory elements from euchromatic chromatin using FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements). Methods 48: 233–239.
16. Tone Y, Kojima Y, Furusho K, Brady M, Yashiro-Ohtani Y, et al. (2007) OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. J Immunol 179: 1760–1767.
17. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, et al. (1991) Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88: 1613–1621.
18. Kouzarides T (2007) Chromatin modifications and their function. Cell 128: 693–705.
19. Goldberg AD, Allis CD, Bernstein E (2007) Epigenetics: a landscape takes shape. Cell 128: 635–638.
20. Suganuma T, Workman J (2011) Signals and combinatorial functions of histone modifications. Annu Rev Biochem 80: 473–499.
21. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, et al. (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315–326.
22. Thierry-Mieg D, Thierry-Mieg J (2006) AcView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 7 Suppl 1: S12 11–14.
23. Morris JF, Raucher EJ, 3rd, Davis B, Klemsz M, Xu D, et al. (1995) The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 86: 3640–3647.
24. Emili A, Greenblatt J, Ingles CJ (1994) Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol Cell Biol 14: 1592–1595.
25. Hoey T, Weinzierl RO, Gill G, Chen JL, Dynlacht BD, et al. (1993) Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell 72: 247–260.
26. Gill G, Pascal E, Tseng ZH, Tjian R (1994) A glutamine-rich hydrophobic patch in transcription factor Sp1 contacts the dTAFII110 component of the Drosophila TFIID complex and mediates transcriptional activation. Proc Natl Acad Sci U S A 91: 192–196.
27. Lania L, Majello B, De Luca P (1997) Transcriptional regulation by the Sp family proteins. Int J Biochem Cell Biol 29: 1313–1323.
28. Kumar AP, Butler AP (1999) Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. Cancer Lett 137: 159–165.
29. Black AR, Black JD, Azizkhan-Clifford J (2001) Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188: 145–160.
30. Wang L, Wei D, Huang S, Peng Z, Le X, et al. (2003) Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9: 6371–6380.
31. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, et al. (2004) Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 15: 4041–4053.
32. Arai N, Naito Y, Watanabe M, Masuda ES, Yamaguchi-Iwai Y, et al. (1992) Activation of lymphokine genes in T cells: role of cis-acting DNA elements that respond to T cell activation signals. Pharmacol Ther 53: 303–318.
33. Brightbill HD, Plevy SE, Modlin RL, Senale ST (2000) A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J Immunol 164: 1940–1951.
34. Tone M, Powell MJ, Tone Y, Thompson SA, Waldmann H (2000) IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol 165: 296–291.
35. Hummelshoj T, Ryder LP, Madsen HO, Odum N, Svejgaard A (2006) A functional polymorphism in the Eta-1 promoter is associated with allele specific binding to the transcription factor Sp1 and elevated gene expression. Mol Immunol 43: 980–986.
36. Dzialo-Hatton R, Milbrandt J, Hockett RD, Jr., Weaver CT (2001) Differential expression of Fas ligand in Th1 and Th2 cells is regulated by early growth response gene and NF-AT family members. J Immunol 166: 4534–4542.
37. Chen GY, Osada H, Santamaria-Babi LF, Kannagi R (2006) Interaction of GATA-3/T-bet transcription factors regulates expression of sialyl Lewis X homing receptors on Th1/Th2 lymphocytes. Proc Natl Acad Sci U S A 103: 16084–16089.
38. Dorado B, Martin-Saavedra FM, Jerz M, Ballester S (2006) The activity of interleukin-4 receptor alpha-chain promoter is regulated by a GT box element. Mol Immunol 43: 1808–1816.
39. Xin ZT, Carroll KA, Kumar N, Song K, Ly H (2011) Transcriptional activation of TINF2, a gene encoding the telomere-associated protein TIN2, by Sp1 and NF-kappaB factors. PLoS One 6: e21333.